Last reviewed · How we verify
NCT07383766
Aesthetic Improvement of Facial Rhytids Using Injectables
Phase 4 trial testing Revanesse® Renew™+ in Aesthetic in 14 participants. Currently enrolling.
25 February 2027
Quick facts
| Lead sponsor | Erevna Innovations Inc. |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 14 |
| Start date | 25 February 2026 |
| Primary completion | 25 February 2027 |
| Estimated completion | 25 March 2027 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Revanesse® Renew™+
Conditions studied
- Aesthetic — all drugs for Aesthetic →
Sponsor
Erevna Innovations Inc. — full company profile →
Who can join
Adults 30 to 75, any sex, with Aesthetic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Revanesse® Renew™+ (Prollenium Medical Technologies Inc.) is a non-crosslinked HA skin booster that combines low- and high-molecular-weight HA at a concentration of 14 mg/mL in a sterile aqueous gel for intradermal injection7. This dual-weight formulation provides both rapid hydration and sustained moisture retention, improving dermal suppleness and promoting subtle textural refinement through physiologic hydration rather than volumization. The present study is designed to compare biweekly and monthly treatment schedules of Revanesse® Renew™+, assessing clinical efficacy, objective biophysical markers, and participant-reported outcomes to inform evidence-based treatment protocols in aesthetic medicine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07383766
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aesthetic
Currently open trials in the same condition.
- NCT07368686 — Topical Multivitamin Serum for Skin Heath · Phase 4 · recruiting
- NCT07210190 — Microneedling for Skin Heath · Phase 4 · recruiting
- NCT07079397 — Hyaluronic Acid Filler Migration · NA · recruiting
- NCT07202117 — PLLA and CaHA-R for Aesthetic Rejuvenation · Phase 4 · recruiting
- NCT07205744 — Post-Menopause Skin Rejuvenation Study · Phase 4 · active not recruiting
Other Erevna Innovations Inc. trials
Trials by the same sponsor.
- NCT07368686 — Topical Multivitamin Serum for Skin Heath · Phase 4 · recruiting
- NCT07210190 — Microneedling for Skin Heath · Phase 4 · recruiting
- NCT07079397 — Hyaluronic Acid Filler Migration · NA · recruiting
- NCT07202117 — PLLA and CaHA-R for Aesthetic Rejuvenation · Phase 4 · recruiting
- NCT07205744 — Post-Menopause Skin Rejuvenation Study · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07383766 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Erevna Innovations Inc.
- Last refreshed: 5 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07383766.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing